Skip to main content
Glama

Lichess

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly, openWorld, idempotent, and non-destructive behavior. The description adds substantial extra behavioral context: it cascades through multiple endpoints, degrades gracefully when enrichment sources fail, returns figi_candidates rather than asserting on ambiguous matches, explicitly reports unresolved identifiers, and labels each identifier with its source. This exceeds what the annotations alone provide.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but it is organized into a front-loaded invocation rule, supported-type sections, and a graceful-degradation note. Most sentences carry semantic weight, though some details could be tightened without losing value.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the burden of explaining what the agent gets back. It covers company and drug outputs, identifier sources, ambiguity behavior, unresolved identifiers, and failure modes. This is complete enough to invoke the tool correctly without additional context.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, and the schema already documents value examples. The description adds meaning beyond the schema by noting that ISIN is also accepted for company inputs, explaining how non-ticker instruments resolve via name matching, and clarifying that a ticker-implied lookup uses the exact ticker map. These details materially help an agent supply the correct parameter values.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with a precise verb and resource: resolve a user-spoken name to canonical/official identifiers. It is clearly differentiated from siblings like compare_entities and entity_profile by its focus on name-to-ID resolution, and it enumerates the exact identifier types (CIK, ticker, LEI, FIGI, RxCUI) it produces.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says to use this tool FIRST whenever a name is present but an ID is needed, and gives concrete query-phrase examples. It does not explicitly name alternative tools to avoid, but it provides enough context that an agent can distinguish this from sibling lookup/research tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Lichess toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.3/5.0
Disambiguation2/5

The server mixes chess tools with numerous data query tools from Pipeworx, causing significant overlap. Multiple ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) and deep_research have similar purposes, making it difficult for an agent to choose correctly. Chess tools are distinct but compete with many unrelated tools.

Naming Consistency2/5

Tool names follow no consistent pattern: chess tools use mostly underscores (top_players, opening_explorer), Pipeworx tools use mixed styles (ask_pipeworx, deep_research, entity_profile), and memory/subscription tools use simple verbs (remember, subscribe). The naming is inconsistent across the set.

Tool Count2/5

With 41 tools, the count is high and unfocused. A chess server would typically have 10-15 tools; the remaining 31 tools from Pipeworx are unrelated and overwhelm the set. The server tries to cover too many domains, making it bloated for its primary purpose.

Completeness2/5

The chess-specific tools (10) cover basic queries but lack deeper chess analysis (e.g., puzzles, board evaluation). The extensive Pipeworx tools are out of scope for a Lichess server, resulting in an incomplete surface for the expected domain and an excessive surface for unrelated data lookups.

Resources